Latest Ratios: P/E Ratio -2.5x · EV/EBITDA N/A · ROE -41.4%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $274M | $203M | $206M | $221M | $136M | $170M | $438M | $376M | $275M | $248M | $344M |
| Enterprise Value | $245M | $174M | $148M | $214M | $115M | $110M | $429M | $374M | $270M | $246M | $338M |
| P/E Ratio → | -2.54 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | 153.92 | 19.09 | 15.72 | 43.58 | 38.83 | 37.58 | 41.91 | 72.22 |
| P/B Ratio | 1.27 | 0.98 | 0.71 | 2.94 | 2.48 | 2.63 | 34.30 | 65.68 | 35.79 | 49.35 | 32.43 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | 149.26 | 16.14 | 10.19 | 42.72 | 38.69 | 36.85 | 41.47 | 70.98 |
| EV / EBITDA | — | — | 14.15 | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | 100.0% | 23.0% | 42.8% | 50.9% | 52.9% | 41.7% | 31.1% | 17.6% |
| Operating Margin | — | — | — | -2855.0% | -213.7% | -68.5% | -34.2% | -35.9% | -72.2% | -113.6% | -132.5% |
| Net Profit Margin | — | — | — | -3243.2% | -206.5% | -66.3% | -31.7% | -33.8% | -66.3% | -113.1% | -129.4% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -41.4% | -41.4% | -43.3% | -71.6% | -24.6% | -18.5% | -34.5% | -48.8% | -76.3% | -85.7% | -45.6% |
| ROA | -33.9% | -33.9% | -36.1% | -59.6% | -23.4% | -17.3% | -26.3% | -36.1% | -57.5% | -67.9% | -40.6% |
| ROIC | -41.4% | -41.4% | 5.2% | -60.1% | -59.4% | -126.4% | -61.2% | -77.9% | -165.5% | -142.2% | -86.5% |
| ROCE | -40.5% | -40.5% | 5.2% | -59.5% | -25.1% | -18.6% | -32.3% | -45.1% | -75.8% | -80.2% | -44.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.01 | 0.03 | — | 0.01 | 0.07 | 0.18 | — | — | — |
| Debt / EBITDA | — | — | 0.39 | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.14 | -0.20 | -0.09 | -0.38 | -0.93 | -0.68 | -0.24 | -0.69 | -0.52 | -0.56 |
| Net Debt / EBITDA | — | — | -5.50 | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -276.73 | -276.73 | -1696.33 | -487.39 | — | -62.11 | — | — | — | — | — |
Net cash position: cash ($31M) exceeds total debt ($2M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.17 | 5.17 | 12.68 | 1.07 | 19.89 | 34.47 | 9.21 | 3.50 | 6.53 | 2.98 | 9.30 |
| Quick Ratio | 5.17 | 5.17 | 12.68 | 1.07 | 19.36 | 33.89 | 8.71 | 3.09 | 6.05 | 2.70 | 9.01 |
| Cash Ratio | 5.05 | 5.05 | 12.45 | 0.59 | 16.35 | 32.71 | 7.18 | 1.52 | 4.75 | 1.87 | 8.11 |
| Asset Turnover | — | — | — | 0.01 | 0.12 | 0.16 | 0.65 | 1.11 | 0.78 | 0.79 | 0.39 |
| Inventory Turnover | — | — | — | — | 3.88 | 5.79 | 7.42 | 7.06 | 8.05 | 7.91 | 12.15 |
| Days Sales Outstanding | — | — | — | 299.08 | 70.03 | 55.69 | 63.10 | 77.07 | 57.59 | 73.46 | 55.66 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $74M | $64M | $55M | $55M | $55M | $55M | $68M | $67M | $55M | $55M |
Clinical Trial Funding Gap
As reported in recent financial filings, CATX trades at a price-to-book ratio of 1.08, a valuation that appears to ignore the company's persistent negative earnings and suggests the market is pricing the firm as a speculative biotech platform rather than a stable medical device manufacturer.
The absence of meaningful P/E or EV/EBITDA multiples reflects the company's current pre-commercial status in its primary radiopharmaceutical pipeline. Investors should monitor whether this valuation floor holds as the company continues to burn cash, as the current market pricing implies a high probability of clinical success that may not be supported by the legacy device business.
Based on reported figures, CATX has consistently posted negative ROIC, reaching -8.9% in 2026Q1, which indicates that the company is currently destroying shareholder value as it aggressively deploys capital into unproven radiopharmaceutical development rather than optimizing its legacy medical device operations.
The persistent negative return on capital suggests that the company's pivot to Lead-212 therapies is not yet generating the operational efficiencies required to offset the high fixed costs of nuclear manufacturing. This trend warrants further investigation into whether the company can achieve a positive return profile before its current cash reserves are exhausted.
According to recent quarterly data, the company's DSO reached 38 days in 2026Q1, while the lack of consistent inventory turnover data suggests that the logistical complexity of managing short-lived isotopes is creating significant friction in the company's ability to convert production into cash.
The high volatility in working capital metrics, including significant outflows, indicates that the company's supply chain is struggling to align with the demands of its radiopharmaceutical pipeline. Investors should monitor these efficiency ratios as a proxy for the company's ability to scale its manufacturing infrastructure without incurring excessive waste.
As indicated by the latest financial statements, the company maintains a current ratio of 8.75 in 2026Q1, yet this headline figure appears misleading given the rapid depletion of cash reserves and the high fixed costs associated with maintaining specialized nuclear regulatory compliance and cleanroom facilities.
While the current ratio suggests a comfortable short-term position, the underlying cash burn rate indicates that this liquidity is rapidly diminishing. The company's reliance on external financing to fund its clinical trials suggests that its liquidity position is highly sensitive to market conditions and the timing of future capital raises.
The most commonly misapplied metric for CATX is the current ratio, which obscures the company's true liquidity risk by failing to account for the high, non-discretionary cash outflows required to maintain the specialized isotope supply chain and ongoing clinical trial commitments.
Analysts should instead focus on the cash burn rate and the remaining runway, as the current ratio provides a false sense of security for a company in a capital-intensive development phase. Relying on traditional liquidity ratios ignores the existential risk posed by the company's reliance on external funding to sustain its operations.
Includes 30+ ratios · 30 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CATX stock.
Perspective Therapeutics, Inc.'s current P/E ratio is -2.5x. This places it at the 50th percentile of its historical range.
Perspective Therapeutics, Inc.'s return on equity (ROE) is -41.4%. The historical average is -52.6%.
Based on historical data, Perspective Therapeutics, Inc. is trading at a P/E of -2.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.